Lupin got USFDA nod for marketing its diarrhea drug vancomycin hydrochloride in US

Feb 3, 2015 14:14 IST

Mumbai-based drug major Lupin Limited on 2 February 2015 announced that it had received final approval from US Food and Drugs Administration (USFDA) for its vancomycin hydrochloride capsules used for treating diarrhea.

The approval was given for the marketing of 125 mg and 250 mg strength of capsules in the US market. Lupin Pharmaceuticals Inc, Lupin’s US subsidiary, would market the generic version of Vancocin capsules of ANI Pharmaceuticals Inc.

Vancomycin is an antibiotic useful for the treatment of a number of bacterial infections. Lupin's vancomycin capsules are indicated for the treatment of C. difficile-associated diarrhoea and also for the treatment of enterocolitis caused by staphylococcus aureus (including methicillin-resistant strains).


Is this article important for exams ? Yes13 People Agreed

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK